Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, April 13, 2015, 39 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $250.00 to $3,812,500.00.

Highlighted Stocks Traded by Insiders:

Thoratec (THOR) - FREE Research Report

Dimick Neil F, who is Director at Thoratec, sold 4,786 shares at $43.00 on April 13, 2015. Following this transaction, the Director owned 36,167 shares meaning that the stake was reduced by 11.69% with the 4,786-share transaction.

The shares most recently traded at $41.22, down $1.78, or 4.32% since the insider transaction. Historical insider transactions for Thoratec go as follows:

  • 4-Week # shares sold: 5,000
  • 12-Week # shares sold: 5,000
  • 24-Week # shares sold: 5,000

The average volume for Thoratec has been 624,000 shares per day over the past 30 days. Thoratec has a market cap of $2.3 billion and is part of the health care sector and health services industry. Shares are up 28.99% year-to-date as of the close of trading on Monday.

Thoratec Corporation, together with its subsidiaries, develops, manufactures, and markets proprietary medical devices used for mechanical circulatory support for the treatment of heart failure patients. The company has a P/E ratio of 47.4. Currently, there are 7 analysts who rate Thoratec a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on THOR - FREE

TheStreet Quant Ratings

rates Thoratec as a

buy

. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Thoratec Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Gordman's Stores (GMAN) - FREE Research Report

Glenn Roger L., who is Senior VP of Human Resources at Gordman's Stores, bought 500 shares at $8.10 on April 13, 2015. Following this transaction, the Senior VP of Human Resources owned 13,900 shares meaning that the stake was boosted by 3.73% with the 500-share transaction.

The shares most recently traded at $8.29, up $0.19, or 2.29% since the insider transaction. Historical insider transactions for Gordman's Stores go as follows:

  • 4-Week # shares bought: 32,300
  • 12-Week # shares bought: 32,300
  • 24-Week # shares bought: 32,300

The average volume for Gordman's Stores has been 193,600 shares per day over the past 30 days. Gordman's Stores has a market cap of $158.4 million and is part of the services sector and retail industry. Shares are up 196.34% year-to-date as of the close of trading on Monday.

Gordmans Stores, Inc. operates department stores under the Gordmans name in the United States. Its merchandise selection includes a range of apparel, footwear, and home fashions products, as well as accessories. Currently, there is 1 analyst who rates Gordman's Stores a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Recommends

Exclusive Offer: Get the latest Stock Analysis on GMAN - FREE

TheStreet Quant Ratings

rates Gordman's Stores as a

sell

. The company's weaknesses can be seen in multiple areas, such as its generally high debt management risk, disappointing return on equity, weak operating cash flow and feeble growth in its earnings per share. Get the full

Gordman's Stores Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Inovio Pharmaceuticals (INO) - FREE Research Report

Cabrera Angel, who is Director at Inovio Pharmaceuticals, bought 8,000 shares at $9.53 on April 13, 2015. Following this transaction, the Director owned 36,750 shares meaning that the stake was boosted by 27.83% with the 8,000-share transaction.

The shares most recently traded at $10.20, up $0.67, or 6.57% since the insider transaction. Historical insider transactions for Inovio Pharmaceuticals go as follows:

  • 4-Week # shares bought: 3,960
  • 12-Week # shares bought: 3,960
  • 24-Week # shares bought: 3,960

The average volume for Inovio Pharmaceuticals has been 898,000 shares per day over the past 30 days. Inovio Pharmaceuticals has a market cap of $594.0 million and is part of the health care sector and drugs industry. Shares are up 7.63% year-to-date as of the close of trading on Monday.

Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases. Currently, there are 6 analysts who rate Inovio Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on INO - FREE

TheStreet Quant Ratings

rates Inovio Pharmaceuticals as a

sell

. The company's weaknesses can be seen in multiple areas, such as its weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full

Inovio Pharmaceuticals Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

null